

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approval for drug production and registration for Metronidazole and Sodium Chloride Injection in form of polypropylene infusion bottle packaging (two specifications including 250ml:1.25g and 100ml:0.5g) from the National Medical Products Administration of China. This packaging of plastic bottle is an addition to the multi-layer co-extrusion film infusion bag which has passed the consistency evaluation. Metronidazole is a commonly used antibiotic, which is mainly used in treatment or prevention of systemic or local infections caused by anaerobic bacteria, and in treatment of anaerobic bacterial infections in abdominal cavity, digestive tract, female reproductive system and oral cavity.

In addition, the Board is also pleased to announce that the Group has obtained the approval from the National Medical Products Administration of China for using the Group’s own bulk drug Rosuvastatin calcium in its production of corresponding preparations product Rosuvastatin Calcium Tablets. Rosuvastatin calcium is mainly used in treatment of primary hypercholesterolemia or mixed dyslipidemia.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board

Chow Hing Yeung

Executive Director and Company Secretary

Hong Kong, 7 September 2022

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.